Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05318196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

Study acronym: NEPHROGENE2
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Mar 28, 2024, no change to tracked fieldsv5-v6
  2. Primary completion date: Apr 1, 2027 to Sep 1, 2027
    • Study completion date: Apr 1, 2032 to Sep 1, 2032
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2022 to Sep 5, 2022
    • Site details revised
    v3
  4. Start date: Apr 1, 2022 to Jul 1, 2022v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.
Trial Details
NCT Number NCT05318196
Lead Sponsor University Hospital, Toulouse
Conditions
(from sponsor)		 Acute Kidney Injury, Chronic Kidney Diseases, Solid-organ Transplantation, Cancer, Metabolic Disease, Immune Diseases
Related terms Acute Kidney Injury, Immune System Diseases, Metabolic Diseases, Neoplasms, Renal Insufficiency, Chronic
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov